--- title: "Investor Materials | Lionheart Longevity Investor Relations" description: "Lionheart Health executive summary, investor presentation and company overview." url: https://investors.lionheartlongevity.com/company --- Company # Investor Materials Lionheart Health is developing a platform that uses programmed bioelectric stimulation to influence the expression and release of proteins associated with regeneration, recovery and healthy aging. ## Key Documents [![Investor presentation cover: Public-Ready Longevity Platform](https://investors.lionheartlongevity.com/_astro/investor-deck-cover.DEDLrJ6F_1VMjFi.webp)Investor PresentationOctober 2026 · Ver 3.0 · PDF · 24 slides · 8 MBView PDF →](https://investors.lionheartlongevity.com/docs/lionheart-investor-deck-oct-2026.pdf) [Private Placement MemorandumOffering terms and risk factors for the Rule 506(c) offering. Please read before investing.Sept 18, 2026 · PDF · 28 pages View PDF](https://investors.lionheartlongevity.com/docs/lionheart-ppm-2026-09-18.pdf)[Executive SummaryTwo-page company research brief: platform, strategy, financial snapshot, milestones and risks.Oct 9, 2026 · PDF · 2 pages View PDF](https://investors.lionheartlongevity.com/docs/lionheart-executive-summary-oct-2026.pdf)[2025 Annual ReportLetter to shareholders, 2025 results and 2026 targets.PDF · 32 pages View PDF](https://investors.lionheartlongevity.com/docs/lionheart-2025-annual-report.pdf) The investor presentation is updated regularly; this page always links to the current version. Executive Summary ## Core thesis Lionheart's initial commercial focus combines regenerative aesthetics and healthspan longevity with clinic services, at-home devices and recurring memberships. Bioelectric-enhanced biologics extend the research strategy beyond device-only interventions. The company's central hypothesis is that selected electrical signals can modulate specific biological pathways rather than deliver a single generic stimulation effect. Proteins of interest include Klotho, follistatin and BDNF, alongside other targets associated with tissue repair, muscle function and brain health. Protocol effects depend on signal parameters, tissue exposure, patient characteristics and treatment context; protein changes must be validated separately from clinical benefit. ## Strategic pillars ### Regenerative aesthetics HairCell and SkinStim programs combine bioelectric stimulation with selected light, electromagnetic, serum and PRF modalities. Clinic protocols and home continuity create multiple product and service opportunities. ### Healthspan longevity Klotho-Up integrates lifestyle, exercise, BodStim EMS, targeted stimulation and biomarker measurement. Muscle, brain and immune function are central outcomes of interest. ### Bioelectric-enhanced biologics Research explores stimulation alongside PRF, peptides and, in advanced investigational programs, cells, gene delivery and secretomes. The aim is to improve biological response; incremental benefit requires controlled testing. Business model ## One platform, multiple routes to market Clinic The Lionheart 240 Stimulus supports a program-based device model. At home The 240 Portable, Brain Band and BodStim support continuity between visits. Recurring Memberships, clinician services, software programs, product sales and clinic licensing offer complementary revenue streams. The investment case depends on converting this breadth into repeat purchases, clinic utilization and durable unit economics. ## Leadership [Profiles →](https://investors.lionheartlongevity.com/governance/leadership) * Howard J. Leonhardt, Executive Chairman & Co-CEO * Scott Hoots, Co-CEO * Scott Jordan, CFO * Dr. Leslie Miller, CMO * Brian Lasater, CTO * Dr. Jorge Genovese, VP Bioelectric Research * Kelsie Leonhardt, Chief NeuroScientist, Manager Research Clinics ## Explore the company [Technology →Bioelectric protein expression, Klotho therapy and Klotho-expressing stem cells, explained.](https://investors.lionheartlongevity.com/company/technology)[Therapeutic Pipeline →54 programs across ten therapeutic areas, by stage of development.](https://investors.lionheartlongevity.com/company/pipeline)[Products & Protocols →Top 25 product families, eShop offerings and licensee clinic protocols.](https://investors.lionheartlongevity.com/company/products)[Manufacturing Partners →The OEM and technology partners behind Lionheart devices and equipment.](https://investors.lionheartlongevity.com/company/manufacturing) Disclosure Company-prepared materials; not an independent research recommendation. Product-specific cleared uses do not establish approval of protein-expression claims, aesthetics or longevity outcomes, or investigational biologic combinations. Forward-looking objectives and forecasts are subject to execution, clinical, regulatory and financing uncertainty.